Inclusion Criteria:

• Be willing and able to sign the informed consent and comply with study procedures.

• Be at least 18 years of age.

• Be scheduled for or planning to have a surgical resection of a lung lesion or mass with diagnostic and/or curative intent.

• Meet all requirements for the planned surgery based on opinion of the surgeon, anesthesiologist, and/or other consulting physician.

• Be able to meet the following conditions:

  • Female participants must be of non-childbearing potential, or,

  • If of childbearing potential, be non-pregnant or non-lactating and agree to use highly effective contraception from screening through Day 30 after treatment.

  • Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days after dosing and agree not to donate semen during this waiting period.

  • Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:

    • Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or

    • Intrauterine device or intrauterine hormone-releasing system

    • NOTE: Participants who abstain from heterosexual intercourse as their usual and preferred lifestyle, will not be required to use contraception as described above. They are required to maintain abstinence from screening through Day 30 after treatment.

    • NOTE: Subjects in a same sex relationship, must use a barrier form of contraception (e.g., condom, diaphragm) to protect against the transfer of the study drug in any bodily fluids.

• Have not participated in an interventional clinical trial within the last 30 days. (NOTE: participation in a disease registry or quality of life study is not exclusionary).

Exclusion Criteria:

• They have a known allergy or reaction to radiographic contrast agents, ICG, or any component of abenacianine.

• They have received chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to study enrollment. NOTE: Exceptions are those agents used to prevent recurrence of certain cancers, e.g. tamoxifen, letrozole, and anastrozole.

• They have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study.

• They are prisoners, institutionalized individuals, or are unable to consent for themselves.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/22/2025. Questions regarding updates should be directed to the study team contact.